alexa Re-thinking Vaccinology
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Geert Vanden Bossche
Keynote: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.019
T o eliminate safety risks related to infectivity, inactivated pathogens and, more suitably, well-characterized pathogen- derived antigens (Ags) have increasingly been used as immunogens in ?modern? vaccines. The selection of these Ags is usually based on their capacity to naturally induce immune responses that ?correlate? with protection.. These Ags, however, are known to be antigenically variable (e.g., conformational Bc epitopes) and/ or subject to immunogenetic restriction (e.g., linear, cell-bound epitopes). In addition, the immunogenicity of ?good? vaccinal Ags is largely dependent on memory CD4 + T helper cells. However, activation of the latter upon natural infection or foreign Ag exposure of genetically predisposed subjects has been associated with immune pathology. Priming of CD4 + T helper cells by adjuvanted vaccines is, therefore, increasingly raising safety concerns. On the other hand, Ags that are highly conserved and of vital importance to the pathogen (hence, called ?protective?) are either not included in contemporary vaccines or not effectively recognized by the host immune system since either deprived of cognate CD4 + T help or outcompeted by other pathogen-derived ?decoy? epitopes for binding to MHC molecules. Hence, we consider that new technologies enabling immune targeting of such protective epitopes by natural, universal (i.e., MHC-nonrestricted) immune helper cells is the new Holy Grail for modern vaccinology.
Geert Vanden Bossche obtained his DVM at the Veterinary Faculty of Ghent and his PhD in Virology at the University of Hohenheim, Stuttgart. Following his Postdoctoral training in virology, immunology and molecular biology at the Free University of Berlin and Hohenheim (Germany), where he subsequently held adjunct faculty appointments, he transitioned to the Vaccine Industry where he served various senior roles in both early and late vaccine development at GlaxoSmithKline Biologicals, Novartis Vaccines & Diagnostics and Solvay Biologicals. He then joined the Bill & Melinda Gates Foundation to serve as SPO in Vaccine Discovery for Global Health. He is founder of UNIVAC LLC in the US and UNIVAC NV in Belgium and visiting scientist at the REGA Institute, University of Leuven (Belgium). He is board certified in virology and microbiology, the author of over 30 publications, and inventor on several patent applications. He has presented vaccine- and adjuvant-related topics at multiple international congresses
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version